564 related articles for article (PubMed ID: 25349172)
1. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment.
Cheng L; Doecke JD; Sharples RA; Villemagne VL; Fowler CJ; Rembach A; Martins RN; Rowe CC; Macaulay SL; Masters CL; Hill AF;
Mol Psychiatry; 2015 Oct; 20(10):1188-96. PubMed ID: 25349172
[TBL] [Abstract][Full Text] [Related]
2. Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer's Disease.
Dong Z; Gu H; Guo Q; Liang S; Xue J; Yao F; Liu X; Li F; Liu H; Sun L; Zhao K
Mol Neurobiol; 2021 Jul; 58(7):3084-3094. PubMed ID: 33629272
[TBL] [Abstract][Full Text] [Related]
3. A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease.
Guo R; Fan G; Zhang J; Wu C; Du Y; Ye H; Li Z; Wang L; Zhang Z; Zhang L; Zhao Y; Lu Z
J Alzheimers Dis; 2017; 60(4):1365-1377. PubMed ID: 29036818
[TBL] [Abstract][Full Text] [Related]
4. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.
Ellis KA; Bush AI; Darby D; De Fazio D; Foster J; Hudson P; Lautenschlager NT; Lenzo N; Martins RN; Maruff P; Masters C; Milner A; Pike K; Rowe C; Savage G; Szoeke C; Taddei K; Villemagne V; Woodward M; Ames D;
Int Psychogeriatr; 2009 Aug; 21(4):672-87. PubMed ID: 19470201
[TBL] [Abstract][Full Text] [Related]
5. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease.
Hara N; Kikuchi M; Miyashita A; Hatsuta H; Saito Y; Kasuga K; Murayama S; Ikeuchi T; Kuwano R
Acta Neuropathol Commun; 2017 Jan; 5(1):10. PubMed ID: 28137310
[TBL] [Abstract][Full Text] [Related]
6. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
Tan L; Yu JT; Tan MS; Liu QY; Wang HF; Zhang W; Jiang T; Tan L
J Alzheimers Dis; 2014; 40(4):1017-27. PubMed ID: 24577456
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Vesicle-Enriched miRNA-Biomarkers Show Improved Utility for Detecting Alzheimer's Disease Dementia and Medial Temporal Atrophy.
Chai YL; Strohm L; Zhu Y; Chia RSL; Chong JR; Suresh DD; Zhou LH; Too HP; Hilal S; Radivoyevitch T; Koo EH; Chen CP; Poplawski GHD
J Alzheimers Dis; 2024; 99(4):1317-1331. PubMed ID: 38788066
[TBL] [Abstract][Full Text] [Related]
9. Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer's disease and controls.
Wu HZY; Thalamuthu A; Cheng L; Fowler C; Masters CL; Sachdev P; Mather KA;
Alzheimers Res Ther; 2020 May; 12(1):59. PubMed ID: 32414413
[TBL] [Abstract][Full Text] [Related]
10. A Machine Learning Approach to Identify a Circulating MicroRNA Signature for Alzheimer Disease.
Zhao X; Kang J; Svetnik V; Warden D; Wilcock G; David Smith A; Savage MJ; Laterza OF
J Appl Lab Med; 2020 Jan; 5(1):15-28. PubMed ID: 31811079
[TBL] [Abstract][Full Text] [Related]
11. A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease.
Piccirella S; Van Neste L; Fowler C; Masters CL; Fripp J; Doecke JD; Xiong C; Uberti D; Kinnon P
J Prev Alzheimers Dis; 2022; 9(3):469-479. PubMed ID: 35841248
[TBL] [Abstract][Full Text] [Related]
12. Blood-based protein biomarkers for diagnosis of Alzheimer disease.
Doecke JD; Laws SM; Faux NG; Wilson W; Burnham SC; Lam CP; Mondal A; Bedo J; Bush AI; Brown B; De Ruyck K; Ellis KA; Fowler C; Gupta VB; Head R; Macaulay SL; Pertile K; Rowe CC; Rembach A; Rodrigues M; Rumble R; Szoeke C; Taddei K; Taddei T; Trounson B; Ames D; Masters CL; Martins RN; ;
Arch Neurol; 2012 Oct; 69(10):1318-25. PubMed ID: 22801742
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease.
Lusardi TA; Phillips JI; Wiedrick JT; Harrington CA; Lind B; Lapidus JA; Quinn JF; Saugstad JA
J Alzheimers Dis; 2017; 55(3):1223-1233. PubMed ID: 27814298
[TBL] [Abstract][Full Text] [Related]
14. The Serum Exosome Derived MicroRNA-135a, -193b, and -384 Were Potential Alzheimer's Disease Biomarkers.
Yang TT; Liu CG; Gao SC; Zhang Y; Wang PC
Biomed Environ Sci; 2018 Feb; 31(2):87-96. PubMed ID: 29606187
[TBL] [Abstract][Full Text] [Related]
15. A blood based 12-miRNA signature of Alzheimer disease patients.
Leidinger P; Backes C; Deutscher S; Schmitt K; Mueller SC; Frese K; Haas J; Ruprecht K; Paul F; Stähler C; Lang CJ; Meder B; Bartfai T; Meese E; Keller A
Genome Biol; 2013 Jul; 14(7):R78. PubMed ID: 23895045
[TBL] [Abstract][Full Text] [Related]
16. Precise profiling of exosomal biomarkers via programmable curved plasmonic nanoarchitecture-based biosensor for clinical diagnosis of Alzheimer's disease.
Song S; Lee JU; Jeon MJ; Kim S; Lee CN; Sim SJ
Biosens Bioelectron; 2023 Jun; 230():115269. PubMed ID: 37001292
[TBL] [Abstract][Full Text] [Related]
17. Detection of multiplex exosomal miRNAs for clinically accurate diagnosis of Alzheimer's disease using label-free plasmonic biosensor based on DNA-Assembled advanced plasmonic architecture.
Song S; Lee JU; Jeon MJ; Kim S; Sim SJ
Biosens Bioelectron; 2022 Mar; 199():113864. PubMed ID: 34890883
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
[No Abstract] [Full Text] [Related]
19. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
[TBL] [Abstract][Full Text] [Related]
20. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers.
Lugli G; Cohen AM; Bennett DA; Shah RC; Fields CJ; Hernandez AG; Smalheiser NR
PLoS One; 2015; 10(10):e0139233. PubMed ID: 26426747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
